Dolphin Medical Services Ltd

As of March 31, 2026, Dolphin Medical Services Ltd carries a market capitalization of 73.69M, placing it among publicly traded companies globally. Its enterprise value stands at 82.20M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, Dolphin Medical Services Ltd has 15.10M shares outstanding.

As of March 31, 2026, Dolphin Medical Services Ltd trades at a trailing price-to-earnings ratio of 121.50. The price-to-sales ratio is 9.91, and the price-to-book ratio stands at 0.73.

As of March 31, 2026, Dolphin Medical Services Ltd trades at an EV/EBITDA multiple of 66.18 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 10.96 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 241.76 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 82.20M versus a market cap of 73.69M, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, Dolphin Medical Services Ltd maintains a current ratio of 2.22, meaning it holds 2.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 8.59, indicating elevated leverage, while an interest coverage ratio of 12.94 demonstrates strong ability to service its debt obligations.

Over the twelve months ended March 31, 2026, Dolphin Medical Services Ltd posted a return on equity (ROE) of 0.61, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 0.31 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 0.50, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 0.65, useful for judging operating efficiency across full business cycles. Inventory turnover of 10.62 indicates how many times Dolphin Medical Services Ltd sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 19, 2026, Dolphin Medical Services Ltd's stock has gained approximately 200.00% over the past 52 weeks. The 50-day moving average sits at 5.42, while the 200-day moving average is 2.92.

Over the twelve months ended March 31, 2026, Dolphin Medical Services Ltd generated 7.50M in revenue and converted that into 612,000.00 in net income, yielding earnings per share of 0.04. EBITDA reached 1.24M, while operating income came in at 340,000.00.

As of March 31, 2026, Dolphin Medical Services Ltd holds 154,500.00 in cash and equivalents against 8.66M in total debt, resulting in a net debt position of 8.52M. Total book value stands at 100.81M, with working capital of 10.87M providing operational flexibility.

Over the twelve months ended March 31, 2026, Dolphin Medical Services Ltd posted a gross margin of 86.82, reflecting its pricing power and cost economics. The operating margin of 4.53 and net profit margin of 8.16 provide insight into operational efficiency.

Dolphin Medical Services Ltd's most recent stock split took place on August 29, 2005 with a 241:388 split ratio.